Welcome to our dedicated page for Core Laboratories SEC filings (Ticker: CLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Core Laboratories Inc. (CLB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Core Laboratories is listed on the New York Stock Exchange under the symbol CLB, and its filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe its financial condition, capital structure, and material events.
Recent 8-K filings referenced by the company include disclosures of quarterly financial results, dividend declarations, and a Ninth Amended and Restated Credit Agreement. That agreement increased the aggregate borrowing commitment, extended the maturity date of the credit facility, and outlined conditions related to outstanding senior notes, while noting that there were no material changes to other key terms such as collateral, pricing, and financial covenants.
Through this page, users can review Core Laboratories’ periodic reports to understand segment performance in Reservoir Description and Production Enhancement, management’s discussion of free cash flow and leverage, and details on capital allocation decisions such as share repurchases and dividends. Current reports on Form 8-K also document events like earnings releases, changes to credit arrangements, and other significant corporate actions.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify information about revenue trends, liquidity, debt facilities, and board-approved dividends. Users can also track updates related to credit agreements and other obligations described in filings, alongside real-time access to new submissions as they appear in the SEC’s EDGAR system.
EARNEST Partners, LLC reported beneficial ownership of 3,221,043 shares of Core Laboratories Inc. common stock, representing 6.9% of the class as of 12/31/2025. The firm has sole voting power over 2,026,540 shares and shared voting power over 298,965 shares.
EARNEST Partners also has sole dispositive power over all 3,221,043 shares and no shared dispositive power. It is filing as an investment adviser and states that no individual client owns more than five percent of the class. The position is certified as held in the ordinary course of business and not for the purpose of changing or influencing control of Core Laboratories.
Core Laboratories Inc. filed a current report stating it issued a press release with its financial results for the fourth quarter of 2025 and the year ended December 31, 2025. The company also announced a quarterly cash dividend of $0.01 per share of common stock.
The dividend will be paid on March 9, 2026 to shareholders of record on February 16, 2026. The related press release is furnished as an exhibit and is not treated as filed or incorporated by reference into other securities law filings unless specifically referenced.
Core Laboratories Inc. reported an insider equity transaction by its Senior Vice President, General Counsel & Secretary on December 31, 2025. A previously granted performance-based restricted share award vested at 116.5% of the target level, resulting in the delivery of 24,952 shares of common stock after the company finished in the 68th percentile for return on invested capital versus its Bloomberg Peer Group for the performance period ending December 31, 2025.
On the same date, 14,310 shares of common stock at a price of $16.03 were withheld or disposed of in a transaction coded "F", typically associated with tax withholding, and the reporting person’s directly held common stock position increased to 41,670.621 shares, with additional small indirect holdings through a custodial account and a 401(k) plan.
Core Laboratories Inc. reported an equity transaction by a senior vice president involving vested performance-based stock awards. On December 31, 2025, 24,952 performance shares with a stated exercise price of $0 were converted into common stock, reflecting the vesting of a February 2023 restricted performance share grant. The company finished in the 68th percentile for return on invested capital within the Bloomberg Peer Group, so the award vested at 116.5% of the target level. On the same date, 19,301 common shares were disposed of in a transaction coded “F” at $16.03 per share, typically indicating shares withheld or sold to cover tax obligations.
Core Laboratories Inc. reported an insider equity transaction by its SVP & CFO. On December 31, 2025, the officer acquired 61,417 shares of common stock at an exercise price of $0 through the vesting of performance-based restricted shares. On the same date, 32,152 shares were disposed of at $16.03 per share, typically reflecting shares withheld to cover taxes associated with the vesting.
The filing shows the officer directly beneficially owning 142,354 shares of Core Laboratories common stock following these transactions. The performance shares were originally granted in February 2023. The company finished in the 68th percentile of return on invested capital relative to its Bloomberg Peer Group for the performance period ending December 31, 2025, leading to vesting at 116.5% of the target award level.
Core Laboratories Inc. (CLB) reported insider equity activity by its Chairman and CEO dated 12/31/2025. The filing shows the vesting and conversion of 180,722 performance shares into common stock at an exercise price of $0, reported under transaction code M, and the disposition of 112,681 common shares at a price of $16.03 per share, reported under code F. Following these transactions, the filing lists direct beneficial ownership amounts of 370,119 shares and 257,438 shares after the respective entries.
The performance shares were originally granted as restricted performance shares in February 2023. The company finished in the 68th percentile for return on invested capital versus a Bloomberg-defined peer group for the performance period ending December 31, 2025. As a result, the performance criteria were satisfied at 116.5% of the target award level, and that number of shares vested on December 31, 2025.
Core Laboratories Inc. CAO & Treasurer reported equity transactions in company stock dated 12/01/2025. The officer had 864 restricted shares convert into common stock at a price of $0, increasing directly held common shares to 8,765.334.
To cover obligations associated with this vesting, 340 common shares were disposed of at $15.39 per share, leaving the officer with 8,425.334 shares before the conversion and 8,765.334 afterward. The filing also shows 6,690 restricted shares remaining, from multiple grants that vest annually over six years as long as the officer continues in service.
Disciplined Growth Investors, Inc. filed Amendment No. 4 to Schedule 13G reporting beneficial ownership of 5,969,860 Core Laboratories (CLB) common shares, representing 12.8% of the class as of 09/30/2025.
The filer reports sole voting power over 5,471,242 shares and sole dispositive power over 5,969,860 shares, with no shared voting or dispositive power. Classified as an investment adviser (IA), the firm certifies the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.
Ariel Investments, LLC filed Amendment No. 8 to Schedule 13G reporting a significant passive stake in Core Laboratories Inc. (CLB). Ariel reports beneficial ownership of 13,773,568 shares, representing 29.4% of the common stock as of the event date.
Ariel has sole voting power over 13,013,344 shares and sole dispositive power over 13,773,568 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Within Ariel’s advised accounts, Ariel Fund holds 6,518,877 shares, representing an economic interest in more than 5% of the class.
Core Laboratories Inc. (CLB): The Vanguard Group filed Amendment No. 3 to Schedule 13G, reporting beneficial ownership of 3,047,390 shares of common stock, representing 6.49% of the class as of 09/30/2025.
Vanguard reports 0 shares with sole voting power and 287,217 shares with shared voting power. It has 2,714,143 shares with sole dispositive power and 333,247 shares with shared dispositive power. Vanguard is identified as an investment adviser (IA), and states the securities were acquired and are held in the ordinary course of business. Vanguard’s clients have the right to receive dividends or sale proceeds related to these shares, and no single client’s interest exceeds 5%. The filing includes a certification that the holdings were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Core Laboratories (CLB)?
What is the market cap of Core Laboratories (CLB)?
